BioVie (BIVI) News Today → With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (From Stocks News) (Ad) Free BIVI Stock Alerts $0.50 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 7:49 PM | finance.yahoo.comBioVie Inc. (BIVI)May 2, 2024 | stockhouse.comInvestors who Lost Money with BioVie Inc. (NASDAQ: BIVI) Shares Should Contact the Shareholders Foundation in Connection with Pending LawsuitApril 29, 2024 | proactiveinvestors.comBioVie secures $13.1M funding from US Department of Defense for Long COVID treatmentApril 29, 2024 | globenewswire.comBioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVIDApril 25, 2024 | finance.yahoo.comBioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker EndpointsApril 25, 2024 | proactiveinvestors.comBioVie presents new data showing lead drug asset may promote healthier agingApril 25, 2024 | globenewswire.comBioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker EndpointsApril 19, 2024 | benzinga.comLatest News for BioVie Stock (NASDAQ:BIVI)April 18, 2024 | globenewswire.comBioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and InflammationMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVIMarch 18, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)March 17, 2024 | stockhouse.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVieMarch 16, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVieMarch 16, 2024 | ca.finance.yahoo.comBIVI Oct 2024 1.500 putMarch 15, 2024 | finance.yahoo.comBIVI Apr 2024 5.000 putMarch 15, 2024 | finance.yahoo.comBIVI Jul 2024 3.500 putMarch 15, 2024 | prnewswire.comShareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVIMarch 14, 2024 | prnewswire.comThe Gross Law Firm Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming DeadlineMarch 14, 2024 | stockhouse.com4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the FirmMarch 13, 2024 | prnewswire.comBIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud LawsuitMarch 12, 2024 | prnewswire.comClass Action Filed Against BioVie Inc. (BIVI) - March 19, 2024 Deadline to Join - Contact Levi & KorsinskyMarch 11, 2024 | proactiveinvestors.comBioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summerMarch 11, 2024 | globenewswire.comBioVie Announces Pipeline Update and Near-Term Clinical PrioritiesMarch 11, 2024 | prnewswire.comBioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVIMarch 9, 2024 | stockhouse.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVieMarch 8, 2024 | markets.businessinsider.comBIOVIE INVESTOR ALERT: Kirby McInerney LLP Alerts BioVie, Inc. (BIVI) Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitMarch 7, 2024 | prnewswire.comContact The Gross Law Firm by March 19, 2024 Deadline to Join Class Action Against BioVie Inc.(BIVI)March 7, 2024 | markets.businessinsider.comATTENTION BIOVIE INC. Shareholders: Securities Fraud Lawsuit Filed Against BioVie Inc. (BIVI)March 6, 2024 | globenewswire.comBioVie Inc. Announces Closing of Public OfferingMarch 6, 2024 | prnewswire.comContact Levi & Korsinsky by March 19, 2024 Deadline to Join Class Action Against BioVie Inc.(BIVI)March 4, 2024 | finance.yahoo.comBIVI Apr 2024 1.500 putMarch 4, 2024 | finance.yahoo.comBIVI Oct 2024 0.500 putMarch 4, 2024 | markets.businessinsider.comBioVie Announces Pricing Of Its Best Efforts Public Offering - Quick FactsMarch 4, 2024 | msn.comWhy BioVie (BIVI) Shares Are Down 40%March 4, 2024 | investorplace.comWhy Is BioVie (BIVI) Stock Down 41% Today?March 4, 2024 | investorplace.comWhy Is BioVie (BIVI) Stock Down 41% Today?March 4, 2024 | msn.comBioVie slumps 18%, prices $21M equity offeringMarch 4, 2024 | markets.businessinsider.comBIOVIE INC. (BIVI) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class ActionMarch 4, 2024 | globenewswire.comBioVie Inc. Announces Pricing of Public OfferingMarch 3, 2024 | finance.yahoo.comBIVI Mar 2024 2.500 callMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVIMarch 1, 2024 | msn.comWhy Is Alzheimer's/Parkinson's Focused BioVie Stock Surging On Friday?March 1, 2024 | globenewswire.comBioVie Inc. Announces Proposed Public Offering of Common StocMarch 1, 2024 | marketbeat.comBioVie Sees Unusually High Options Volume (NASDAQ:BIVI)BioVie Inc. (NASDAQ:BIVI - Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock investors purchased 12,329 call options on the company. This is an increase of approximately 1,033% compared to the average volume of 1,088 call options.March 1, 2024 | msn.comBioVie jumps as Alzheimer’s drug selected for presentationsMarch 1, 2024 | investorplace.comWhy Is BioVie (BIVI) Stock Up 100% Today?March 1, 2024 | proactiveinvestors.comBioVie shares surge on lead asset NE3107's potential to improve Parkinson's Disease symptomsMarch 1, 2024 | globenewswire.comBioVie's NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson's Disease Patients and May Be Realigning Physiological Processes for Alzheimer's Patients in Data to be Presented at the International Conference on Alzheimer's and Parkinson's Diseases 2024February 29, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for BioVie Inc. (BIVI) InvestorsFebruary 29, 2024 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. BIVI Media Mentions By Week BIVI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIVI News Sentiment▼0.770.55▲Average Medical News Sentiment BIVI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIVI Articles This Week▼43▲BIVI Articles Average Week Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KALA BIO News Today Galecto News Today GlycoMimetics News Today Flora Growth News Today NanoViricides News Today NeuroBo Pharmaceuticals News Today Aptorum Group News Today Orgenesis News Today Alaunos Therapeutics News Today MEI Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIVI) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersGold Set to EXPLODE!Gold Safe ExchangeCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
